Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-04-14 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
独立董事提名人声明与承诺
Board/Management Information Classification · 100% confidence The document is a formal announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. nominating an independent director candidate for the company's board. It includes detailed statements and commitments regarding the nominee's qualifications, independence, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management information, specifically the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and does not indicate it is a report or announcement of a report publication, so it is not RPA or RNS.
2024-04-14 Chinese
董事会制度
Governance Information Classification · 100% confidence The document is titled '董事会制度' which translates to 'Board of Directors System' or 'Board Rules'. It details the structure, powers, meeting procedures, voting rules, and responsibilities of the company's board of directors. It includes sections on board composition, meeting convocations, decision-making processes, and record-keeping. There is no financial data, audit information, or report publication mentioned. The document is a governance-related internal rules document for the board. Therefore, it fits the category of Governance Information (CGR). The document length (7879 characters) supports it being a full governance document rather than a brief announcement or notice.
2024-04-14 Chinese
股东大会制度
Governance Information Classification · 95% confidence The document is a detailed set of rules and procedures governing the shareholders' meeting (股东大会制度) of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It covers the organization, rights, voting procedures, and execution of shareholder meetings. It is not a report of financial results, audit, or earnings, nor is it a simple announcement or voting result. It is a governance document related to the internal rules and structure of the company's shareholder meetings and board interactions. Therefore, it fits best under Governance Information (CGR). The document length and content confirm it is a full governance report, not a brief notice or announcement.
2024-04-14 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System'. It is a detailed internal policy document outlining the principles, procedures, and governance related to related party transactions within the company. It includes sections on definitions, principles, approval processes, disclosure requirements, and responsibilities of directors and shareholders. The document is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for managing related party transactions. Therefore, it fits best under the category of Governance Information (CGR). The document length (8599 characters) and content confirm it is a substantive policy document rather than a brief announcement or regulatory filing.
2024-04-14 Chinese
董事会秘书工作制度
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作制度' which translates to 'Board Secretary Work System'. It details the rules, responsibilities, appointment, and dismissal procedures for the company's board secretary. It includes references to company law, regulatory requirements, and internal governance practices. There is no financial data, no mention of financial results, no voting results, no announcements of reports, or any other regulatory filings. The document is a governance-related internal policy document approved by the board. The length is about 3500 characters, which is relatively short and consistent with a governance policy document rather than a full report. Therefore, the document fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-14 Chinese
2023年度独立董事述职报告（陈汉文）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2023 by an independent director of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the director's attendance at board and shareholder meetings, opinions on various board resolutions, participation in audit committee meetings, communication with internal audit and accounting firms, and efforts to protect investor rights. The content focuses on the independent director's duties and activities rather than presenting financial statements or audit results. It is not an annual report, audit report, or financial report. It is a formal report by a board member about their role and activities, which fits best under Board/Management Information (MANG). The document length is 3576 characters, which is relatively short but contains substantive content about board activities, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.